STORM Therapeutics Announces Clinical Milestone and New CMO Appointment
Company - People | May 27, 2025 | Top Technology Ventures Ltd
STORM Therapeutics has announced a significant clinical milestone with the first patient being dosed in their clinical collaboration to evaluate STC-15. This collaboration involves examining the combination of STC-15 with LOQTORZI®. Concomitantly, STORM Therapeutics has appointed Dr. Atif Abbas as their Chief Medical Officer. STORM Therapeutics is supported by Top Technology Ventures Ltd., which signals confidence in STORM's innovative research direction and leadership. The appointment of Dr. Abbas is anticipated to drive further advancements in the company's medical strategies.
Sectors
- Biotechnology
- Private Equity
Geography
- United Kingdom – STORM Therapeutics Ltd. and Top Technology Ventures Ltd. are both likely based in the UK, highlighting the country’s active involvement in the biotech sector.
Industry
- Biotechnology – The article primarily revolves around STORM Therapeutics, which is involved in the development of therapeutic solutions at a biotechnology level.
- Private Equity – Top Technology Ventures Ltd. acts as the private equity firm involved by backing STORM Therapeutics, indicating the financial interest and investments in the healthcare sector.
Financials
- – No specific financial details are disclosed in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| STORM Therapeutics Ltd. | Target company | Company | A biotechnology firm that focuses on therapeutic discoveries and innovations. |
| Top Technology Ventures Ltd. | Private Equity Firm | Company | A private equity firm providing financial backing to STORM Therapeutics Ltd. |
| Atif Abbas, M.D. | Chief Medical Officer | Person | Recently appointed CMO at STORM Therapeutics, tasked with leading the company’s medical strategies. |